Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3 (HPV-003)

This study has been completed.
Information provided by (Responsible Party):
Inovio Pharmaceuticals Identifier:
First received: February 16, 2011
Last updated: February 22, 2016
Last verified: February 2016